For these individuals, severe chronic pain acts as an unrelenting disruptor, degrading sleep, impairing physical mobility, and casting a shadow over professional and family life. Yet, despite the clear agony experienced by patients, many physicians hesitate to prescribe opioids. This hesitation is frequently driven by an overarching fear of causing addiction, even in clinical scenarios where alternative treatments have already failed to provide relief.
The opioid epidemic taught the medical community painful, hard-fought lessons about the dangers of indiscriminate prescribing. But as the pendulum swung toward caution, a critical question has emerged: Have we gone too far in the opposite direction? Clinicians, patient advocates, and researchers are increasingly asking whether modern medicine has confused normal physiological dependence with opioid use disorder (OUD), thereby drastically exaggerating addiction risks for patients who are taking their prescribed medications appropriately. Growing patient complaints and a wave of new medical studies suggest that this overcorrection is indeed happening.
Recent Research and Diagnostic Nuances
A significant 2026 study conducted by Yarborough and colleagues examined 1,952 patients receiving long-term opioid therapy through 10 major U.S. health systems. The researchers followed these participants for a full year, utilizing structured diagnostic interviews specifically adapted for patients being actively treated for pain.
When applying pain-adjusted criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the researchers found that 1.54 percent of the cohort developed moderate-to-severe OUD over the course of a year. However, when unadjusted criteria were used, that figure jumped to 4.46 percent. This reveals a nearly threefold difference in estimated addiction risk, depending entirely on how OUD is diagnosed in a clinical setting.
This discrepancy highlights a foundational misunderstanding that has persisted across medical fields for years. Patients who take opioids on a chronic basis naturally develop a physiological tolerance to the medication. Consequently, they often exhibit clear withdrawal symptoms if their opioid dosage is reduced or abruptly stopped. However, these pharmacological adaptations do not constitute an addiction. The DSM-5 explicitly excludes normal physical tolerance and withdrawal when they occur during the course of appropriate, medically supervised treatment.
When a patient takes additional medication due to intense or chronic pain, the situation demands careful clinical evaluation rather than immediate punitive assumptions. Such behavior may reflect a misdiagnosis or inadequate pain analgesia that requires adjustment. Alternatively, it can sometimes serve as an indicator of misuse or a developing addiction. These represent fundamentally different clinical diagnoses that require distinct approaches.
Look to Science
To fully understand the scope of the issue, researchers have repeatedly turned back to broad scientific literature. A 2018 systematic review by Higgins and colleagues analyzed 12 studies involving more than 310,000 patients, establishing a pooled incidence of iatrogenic opioid dependence or abuse of 4.7 percent.
Years later, a comprehensive 2024 review led by Kyla H. Thomas and colleagues at the University of Bristol Medical School evaluated 148 studies encompassing more than 4.3 million patients suffering from chronic noncancer pain. That review estimated a combined dependence and OUD prevalence of 9.3 percent, alongside 29.6 percent for related symptoms and 22 percent for aberrant drug-related behaviors.
Experts note that the prevalence of OUD among patients already receiving opioids is distinct from the incidence of newly diagnosed OUD, and neither metric establishes a definitive lifetime addiction risk when a treatment regimen first begins. While these data points naturally cause concern among healthcare providers, encountering problematic medication-taking behavior does not automatically equate to a formal diagnosis of OUD.
Pain and Addiction: A Problem Recognized Years Ago
The intersection of chronic pain and substance use is not a newly discovered phenomenon. In 2010, researchers and anesthesiology pain clinic colleagues at the University of Florida (UF) published a landmark paper titled "Crossroads of Pain and Addiction" in the journal Pain Medicine. Drawing directly from extensive clinical experiences, the authors argued that chronic pain and addiction frequently coexist. They maintained that physicians must be equipped to assess and treat both conditions simultaneously, rather than operating under the false assumption that simply restricting opioid prescriptions would prevent addiction.
The multidisciplinary pain clinic experience at UF demonstrated that the critical factors determining patient outcomes were individual vulnerability, current and previous substance use disorders (SUDs), opioid selection, delivery methods, timing, and environmental influences.
That work emphasized a clear distinction between psychological addiction and physiological dependence, issuing a strong call for integrated pain and addiction care. The authors argued that pain specialists required foundational training in addiction medicine, while addiction specialists needed to develop greater expertise in comprehensive pain management. More than 15 years later, these lessons remain urgently relevant. Simply reducing prescriptions without simultaneously improving diagnostic accuracy, clinical training, and continuity of care falls far short of comprehensive medical treatment.
Overdose Risk Perceptions
Subsequent research into pain and addiction conducted by the author alongside colleagues at Washington University uncovered a troubling trend: patients receiving opioids for chronic pain frequently underestimate their own personal risk of overdose. In an observational study involving 190 chronic pain patients managed with higher-dose opioids, benzodiazepines, or a combination of both, an astounding 62.1 percent believed they faced zero risk of overdose. More than half of these individuals were concurrently prescribed benzodiazepines, yet fewer than half recognized the documented dangers of combining these central nervous system depressants.
In a related 2023 study, researchers compared these chronic pain patients with a cohort of 152 individuals who had a documented history of OUD. Within the OUD group, only 19.1 percent perceived themselves as having no overdose risk, contrasting sharply with the 62.1 percent observed among the chronic pain patients.
These observational surveys identified a dangerous gap between objective medical risks and patient perceptions. Experts emphasize that an individual does not need to be addicted to suffer a fatal or non-fatal overdose. In fact, opioid-naive or recently detoxified patients carry an elevated risk of respiratory depression when exposed to opioids. Consequently, naloxone education and widespread access are essential components of care for anyone prescribed these medications. The medical community must avoid falling into two parallel traps: diagnosing addiction when a patient exhibits only physical dependence, and conversely, overlooking legitimate overdose risks simply because a patient does not meet the clinical definition of being addicted.
Untreated Pain
The consequences of overly restrictive prescribing practices extend far beyond undertreated physical symptoms. A 2025 report by Matthew Carrillo and colleagues at Penn State surveyed 1,001 chronic pain patients and found that more than half reported significant difficulty obtaining necessary pain medication through legal medical channels. Some respondents admitted to seeking opioid pain medication from illicit sources, while nearly half reported that they had contemplated suicide due to their unrelenting suffering.
Another observational study published in 2025 by Wei and colleagues revealed that unrelieved pain among older adults prescribed opioids was closely associated with heightened risks of developing OUD and experiencing accidental overdoses. Untreated pain fails entirely as an addiction-prevention strategy. Public health analyses consistently estimate that chronic pain acts as a contributing or primary factor in 8.8 to 10.2 percent of all recorded suicide cases across the United States.
Opioid Stigma
Navigating this terrain is further complicated by social and professional attitudes. A 2026 study led by Sarah Gutkind and colleagues at Weill Cornell Medicine surveyed both chronic pain patients and the physicians who treat them, focusing on the perceived stigma surrounding prescription opioids.
The findings revealed a striking divergence: physicians were significantly more likely than patients to anticipate stigma and unfair treatment regarding the prescribing or use of opioids. Nearly half of the surveyed physicians—49.8 percent—anticipated negative judgments, compared with just 29.8 percent of patients. While this study measured perceived stigma rather than actual prescribing actions, these underlying concerns about judgment inevitably shape the environment in which delicate pain management decisions are made.
Interestingly, both groups perceived a slightly greater level of social stigma associated with medical cannabis than with prescription opioids. However, newer studies indicate that when cannabis and opioids are co-prescribed for chronic pain management, opioids are frequently the medications that ultimately get discontinued.
Individualizing Treatment
A 2017 CDC study found that approximately 6 percent of patients who were prescribed opioids for at least one day continued their treatment a full year later. However, continued opioid use is not synonymous with addiction. Prescription records alone cannot reveal who has developed an OUD, who is genuinely benefiting from long-term therapy, or who is experiencing negative side effects.
The CDC’s initial 2016 opioid prescribing guidelines were frequently applied far too rigidly by healthcare systems, often stretching well beyond their intended scope. Recognizing this, the agency revised the guidelines in 2022 to reflect a more nuanced clinical reality.
Comprehensive programs, such as the multidisciplinary pain model formerly utilized at the University of Florida, demonstrate the value of evaluating the whole person. Physicians are encouraged to thoroughly assess pain levels, functional capacity, treatment response, and underlying addiction risk factors—including past substance use disorders, psychiatric illnesses, overdose histories, and concurrent sedative use. Available treatment alternatives must also be considered, including non-opioid medications, physical therapy, rehabilitation programs, and psychological interventions.
Long-term opioid therapy carries uncertain long-term benefits alongside significant risks, particularly for many chronic pain conditions. While a subset of patients genuinely benefit, most do not. Newer research does not render opioids inherently safe; rather, it serves as a timely reminder that physical dependence, misuse, and true addiction are fundamentally distinct medical diagnoses.
Fortunately, medical pain treatment continues to evolve. In January 2025, the U.S. Food and Drug Administration approved Journavx (suzetrigine), a first-in-class, non-opioid analgesic representing an entirely new therapeutic option for acute pain management, free from opioid-mediated respiratory depression or addiction risks.
Ultimately, modern clinical treatment must be individualized, guided by realistic goals, appropriate trials of newer alternatives, regular reassessment, and professional flexibility for the patients who genuinely derive sustained benefit from long-term opioid therapy. The overarching objective remains clear: achieving better pain relief, more accurate addiction diagnosis, safer prescribing practices, and improved overall clinical outcomes.
